DUARTE, Calif.--(BUSINESS WIRE)--The Indo-American Cancer Association (IACA) honored City of Hope’s Ravi Salgia, M.D., Ph.D., with the IACA Award for Outstanding Contributions to Oncology during its annual meeting, which took place during the American Society of Clinical Oncology’s (ASCO) 2017 annual meeting in Chicago.
Salgia, the Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology and the associate director for clinical sciences in City of Hope's comprehensive cancer center, also served as the keynote speaker at the IACA meeting on Saturday, June 3.
“It is an honor to receive this award from the IACA,” Salgia said. “City of Hope appreciates IACA’s recognition of the critical oncology research that is underway.”
Salgia has over 25 years of accomplishments in translational research and the development of targeted therapies to improve the quality of life and survival of cancer patients, especially as related to small cell lung cancer, the IACA noted. Salgia was the first to clone the focal adhesion protein paxillin and also localize the gene to 12q24, the organization added. His laboratory also identified the gain-of-function mutations of paxillin in lung cancer, defined receptor tyrosine kinases and identified unique targets in lung cancer such as MET/RON and EPHB4 receptor tyrosine kinases.
At City of Hope, Salgia plays a key leadership role in the expansion of clinical programs at City of Hope’s Duarte, California, campus and in its clinics throughout Southern California, and has helped lead the integration of state-of-the-art therapeutics with leading-edge research. Salgia works closely with faculty to support both basic research and clinical studies aimed at discovering new cancer treatments.
Board-certified in both internal medicine and medical oncology, Salgia serves on various panels for the National Cancer Institute. He has consistently received research grants from the National Institutes of Health for his research work and has been awarded several invention discoveries and patents related to his work. He is the current chief editor for Cancer Commons, and the co-chief editor for the Journal of Carcinogenesis. Salgia also serves on the editorial advisory board of four additional journals. He has authored 286 peer-reviewed articles, reviews and editorials, one book and 34 book chapters.
Salgia is frequently invited to present his work at national and international conferences and symposia and is the recipient of several honors and awards.
Salgia also chaired two ASCO sessions, one on value-based medicine and integration of tumor biology and another on tumor biology.
About City of Hope
City of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as one of only 48 comprehensive cancer centers, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the world. City of Hope is located in Duarte, California, just northeast of Los Angeles, with community clinics throughout Southern California. It is ranked as one of "America's Best Hospitals" in cancer by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation, diabetes and numerous breakthrough cancer drugs based on technology developed at the institution. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.